trending Market Intelligence /marketintelligence/en/news-insights/trending/hy1Gx0t_68yiCvDbDr2bQw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Immunic uses option to license Daiichi Sankyo's intestinal disease drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Immunic uses option to license Daiichi Sankyo's intestinal disease drug

Immunic Inc. has obtained the sole global rights to commercialize Daiichi Sankyo Co. Ltd.'s intestinal disease treatment IMU-856.

Immunic's subsidiary Immunic AG exercised an option in its licensing agreement with Daiichi to receive rights to the oral therapy, which regulates DNA to RNA in the intestine. The drug aims to restore the intestinal barrier, which keeps potentially harmful bacteria separated in its own space, while maintaining the body's normal immune response.

As part of the agreement, Immunic will pay an up-front licensing fee to Daiichi Sankyo, which is also is eligible to receive performance-based milestone payments in the future and royalties on the sale of IMU-856.

Financial terms of the agreement have not been disclosed.

Immunic intends to start IMU-856's phase 1 clinical trials in the first half of this year.